Rainbow Childrens Medicare Ltd

3 published calls

• PL CapitalBUY04 Aug 2026

  1,5461,900+22.9%

  RAINBOW reported strong Q1FY27 EBITDA with growth of 30% YoY, aided by organic growth of 24% YoY. Profitability is expected to improve from FY27 with a 22% EBITDA CAGR over FY26-28E as new capacities ramp up, leading to a maintained 'BUY' rating with a revised target price of INR 1,900/share.

• Mirae Asset SharekhanBUY04 Aug 2026

  1,5221,722+13.1%

  Focus remains on ramping up the new hospitals. We value the stock at a historic average 1-yr fwd P/E of 46x on FY8E EPS of Rs. 37.4 and arrive at a target price of Rs. 1,722.

• Axis SecuritiesHOLD03 Aug 2026

  1,5251,625+6.6%

  Rainbow reported Q1FY27 revenue and earnings below expectations, impacted by seasonal softness and muted growth in mature assets. Management remains confident in its long-term trajectory, targeting 20% medium-term revenue growth and a return to 55-60% occupancy levels.

Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.